CY1111740T1 - Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων - Google Patents
Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιωνInfo
- Publication number
- CY1111740T1 CY1111740T1 CY20111100737T CY111100737T CY1111740T1 CY 1111740 T1 CY1111740 T1 CY 1111740T1 CY 20111100737 T CY20111100737 T CY 20111100737T CY 111100737 T CY111100737 T CY 111100737T CY 1111740 T1 CY1111740 T1 CY 1111740T1
- Authority
- CY
- Cyprus
- Prior art keywords
- trp
- missing
- phe
- lys
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 239000000863 peptide conjugate Substances 0.000 abstract 3
- 102400001111 Nociceptin Human genes 0.000 abstract 1
- 108090000622 Nociceptin Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000944 | 2000-06-16 | ||
| DKPA200001485 | 2000-10-05 | ||
| US25167100P | 2000-12-06 | 2000-12-06 | |
| EP01952155A EP1294746B1 (en) | 2000-06-16 | 2001-06-15 | Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111740T1 true CY1111740T1 (el) | 2015-10-07 |
Family
ID=27222400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100737T CY1111740T1 (el) | 2000-06-16 | 2011-07-28 | Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1294746B1 (enExample) |
| JP (1) | JP4624639B2 (enExample) |
| AT (1) | ATE508138T1 (enExample) |
| AU (1) | AU7294401A (enExample) |
| CA (1) | CA2410224C (enExample) |
| CY (1) | CY1111740T1 (enExample) |
| DE (1) | DE60144561D1 (enExample) |
| WO (1) | WO2001098324A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550425B2 (en) | 2000-06-16 | 2009-06-23 | Zealand Pharma A/S | Diuretic peptide conjugates |
| US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
| WO2003030828A2 (en) | 2001-10-09 | 2003-04-17 | Synvax, Inc. | Nociceptin-based analgesics |
| WO2003097857A2 (en) * | 2002-05-17 | 2003-11-27 | Zealand Pharma A/S | Method for the detection of aquaretic compounds |
| US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
| JP2006514649A (ja) * | 2003-12-17 | 2006-05-11 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 腎症の治療および予防のための組成物 |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2012065082A1 (en) * | 2010-11-11 | 2012-05-18 | Massachusetts Institute Of Technology | Dendrimer-based excipients for the attentuation of protein aggregation |
| WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| EP3065757A4 (en) | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| CN103936838B (zh) * | 2014-04-10 | 2015-10-28 | 武汉启瑞科技发展有限公司 | 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用 |
| GB201506380D0 (en) | 2015-04-15 | 2015-05-27 | Serodus Asa | Materials and methods for treatment of pulmonary hypertension |
| CA3209741A1 (en) * | 2021-02-26 | 2022-09-01 | Shohei Koide | Compositions and methods comprising antibodies that bind to covalent peptide conjugates |
| WO2025037992A1 (en) * | 2023-08-13 | 2025-02-20 | Filip Majewski | New peptides and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| AU2712999A (en) * | 1998-03-05 | 1999-09-20 | Novo Nordisk A/S | Use of hexapeptides for the manufacture of a pharmaceutical composition for the treatment of hot flushes |
| EP1950224A3 (en) * | 1998-03-09 | 2008-12-17 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| CN1254234C (zh) * | 2000-06-09 | 2006-05-03 | 莱古伦公司 | 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中 |
| US7459539B2 (en) * | 2000-12-15 | 2008-12-02 | Agensys, Inc. | Antibody that binds zinc transporter protein 108P5H8 |
-
2001
- 2001-06-15 DE DE60144561T patent/DE60144561D1/de not_active Expired - Lifetime
- 2001-06-15 EP EP01952155A patent/EP1294746B1/en not_active Expired - Lifetime
- 2001-06-15 AU AU7294401A patent/AU7294401A/xx active Pending
- 2001-06-15 JP JP2002504279A patent/JP4624639B2/ja not_active Expired - Fee Related
- 2001-06-15 WO PCT/US2001/019113 patent/WO2001098324A1/en not_active Ceased
- 2001-06-15 CA CA2410224A patent/CA2410224C/en not_active Expired - Fee Related
- 2001-06-15 AT AT01952155T patent/ATE508138T1/de active
-
2011
- 2011-07-28 CY CY20111100737T patent/CY1111740T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2410224C (en) | 2013-08-13 |
| JP4624639B2 (ja) | 2011-02-02 |
| CA2410224A1 (en) | 2001-12-27 |
| WO2001098324A8 (en) | 2002-03-21 |
| AU7294401A (en) | 2002-01-02 |
| ATE508138T1 (de) | 2011-05-15 |
| DE60144561D1 (de) | 2011-06-16 |
| EP1294746A1 (en) | 2003-03-26 |
| EP1294746B1 (en) | 2011-05-04 |
| JP2004516811A (ja) | 2004-06-10 |
| WO2001098324A1 (en) | 2001-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111740T1 (el) | Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων | |
| ES2194861T3 (es) | Peptidos opiodes. | |
| TW251274B (enExample) | ||
| LU90425I2 (fr) | Cetrorelix et ses seis et d-riv-s pharmaceutiquement acceptables sp-cialement l'ac-tate de c-trorelix | |
| GR3015866T3 (en) | Nonapeptide bombesin antagonists. | |
| KR830004216A (ko) | 아실펩타이드의 제조방법 | |
| AU759442B2 (en) | Novel LHRH antagonists with improved solubility characteristics | |
| GB1570210A (en) | Peptides | |
| NZ335879A (en) | Somatostatin antagonist peptides having a D-amino acid at the second residue | |
| DK0745093T3 (da) | Hidtil ukendte oligopeptoder med affinitet til opioidreceptorer | |
| US4087419A (en) | Heptapeptides and methods for their production | |
| TR199901831T2 (xx) | Kollagen-II'ye �zg� bir T-h�cresi epitopundan olu�an peptitler. | |
| CA1181395A (en) | Lh-rh antagonists | |
| CS207570B2 (en) | Method of making the tetradecapeptide | |
| KR870007206A (ko) | 폴리펩타이드 화합물 | |
| IT1256247B (it) | Peptidi ciclici | |
| KR850006940A (ko) | 레닌 억제제의 제조방법 |